First-trimester exposure to bupropion and risk of cardiac malformations

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 10, 2014, Pages 1066-1075

  Louik, Carol ^a   Kerr, Stephen ^a   Mitchell, Allen A ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Antidepressants; Bupropion; Cardiac malformations; Pharmacoepidemiology

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT;

ADULT; AORTIC COARCTATION; ARTICLE; CARDIOVASCULAR RISK; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INDICATION; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE SEPTUM DEFECT; HIGH RISK INFANT; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; INFANT; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADVERSE EFFECTS; CHEMICALLY INDUCED; ENVIRONMENTAL EXPOSURE; FACTUAL DATABASE; HEART DEFECTS, CONGENITAL; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; RISK; STATISTICAL MODEL; UNITED STATES; YOUNG ADULT;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DATABASES, FACTUAL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; RISK; UNITED STATES; YOUNG ADULT;

EID: 84911807135     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3661     Document Type: Article

References (22)

1. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997; 45: 19-30.
2. Gotlib IH, Whiffen VE, Mount JH, Milne K, Cordy NI. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989; 57: 269-274.
3. Marcus SM, Heringhausen JE. Depression in childbearing women: when depression complicates pregnancy. Prim Care 2009; 36: 151-165, ix.
4. Chung TK, Lau TK, Yip AS, Chiu HF, Lee DT. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001; 63: 830-834.
5. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010; 67: 1012-1024.
6. Yonkers KA, Wisner KL, Stewart DE, et al.. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31: 403-413.
7. Dayan J, Creveuil C, Marks MN, et al.. Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med 2006; 68: 938-946.
8. Diego MA, Field T, Hernandez-Reif M, Schanberg S, Kuhn C, Gonzalez-Quintero VH. Prenatal depression restricts fetal growth. Early Hum Dev 2009; 85: 65-70.
9. Rahman A, Iqbal Z, Bunn J, Lovel H, Harrington R. Impact of maternal depression on infant nutritional status and illness: a cohort study. Arch Gen Psychiatry 2004; 61: 946-952.
10. Wisner KL, Sit DK, Hanusa BH, et al.. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166: 557-566.
11. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 2684-2692.
12. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 1075-1085.
13. Diav-Citrin O, Shechtman S, Weinbaum D, et al.. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66: 695-705.
14. Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 2010; 30: 249-260.
15. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675-2683.
16. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118: 111-120.
17. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289-1296.
18. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: b3569.
19. The Bupropion Pregnancy Registry. Final report: 1 September 2007 through 31 March 2008, Wilmington, NC, 2008.
20. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 474-484.
21. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010; 203: 52 e1-52 e6.
22. Botto LD, Lin AE, Riehle-Colarusso T, Malik S, Correa A. Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol 2007; 79: 714-727.